Healthcare
Live Price
Offline$16.58
-0.78% today
1Y Change
+57.43%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Theravance Biopharma, Inc. (TBPH) is a Healthcare stock with a market cap of $860.00M and listed on NASDAQ. The stock last traded around $16.58 and up 57.4% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +66.9%, EPS growth of +282.6%, a dividend yield of 0.0%. What stands out right now is revenue +66.9%, EPS +282.6%, free cash flow +2109.8% with operating margin -12.3% and ROIC -2.4%. Valuation already assumes a fairly strong business story at P/E 8.1 and price/sales 8.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TBPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TBPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TBPH Max Drawdown
-34.57%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TBPH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$55.3M
+7.7% YoY
FY Net Income
-$199.4M
-122.9% YoY
Free Cash Flow
-$211.3M
-12.6% YoY
Revenue Growth
+66.9%
EPS Growth
+282.6%
Gross Margin
94.9%
Net Margin
98.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 107M | 64M | 57M | 51M | 55M |
| Gross Profit | 102M | 64M | 17M | -12M | -138M |
| Operating Income | -13M | -47M | -56M | -92M | -258M |
| EBITDA | -8M | -38M | -52M | -76M | -233M |
| Net Income | 106M | -56M | -55M | 872M | -199M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 168M | 38M | 40M | 298M | 90M |
| Total Assets | 486M | 354M | 382M | 607M | 375M |
| Total Liabilities | 189M | 179M | 169M | 166M | 713M |
| Shareholder Equity | 297M | 176M | 213M | 442M | -339M |
| Total Debt | 75M | 50M | 49M | 52M | 670M |
| Net Debt | -92M | 12M | 10M | -246M | 580M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
208M
-11.2% YoY
Capital Expenditures
3M
-495.5% YoY
Free Cash Flow
211M
-12.6% YoY
Key ratios
Gross Margin
94.9%
Operating Margin
-12.3%
Net Margin
98.5%
ROE
46.0%
Debt / Equity
0.25x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.